Piperidine renin inhibitors: From leads to drug candidates

Farmaco

Volumn 56, Issue 1-2, 2001, Pages 21-27

  Marki H P ^a   Binggeli, A ^a   Bittner, B ^a   Bohner Lang, V ^a   Breu, V ^a   Bur, D ^a   Coassolo, Ph ^a   Clozel, J P ^a   D'Arcy, A ^a   Doebeli, H ^a   Fischli, W ^a   Funk, Ch ^a   Foricher, J ^a   Giller, T ^a   Gruninger F ^a   Guenzi, A ^a   Guller R ^a   Hartung, T ^a   Hirth, G ^a   Jenny, Ch ^a   Kansy, M ^a   Klinkhammer, U ^a   Lave, T ^a   Lohri, B ^a   Luft, F C ^b   Mervaala, E M ^b   Muller D N ^b   Muller M ^a   Montavon, F ^a   Oefner, Ch ^a   Qiu, C ^a   Reichel, A ^a   Sanwald Ducray, P ^a   Scalone, M ^a   Schleimer, M ^a   Schmid, R ^a   Stadler, H ^a   Treiber, A ^a   Valdenaire, O ^a   Vieira, E ^a   Waldmeier, P ^a   Wiegand Chou, R ^a   Wilhelm, M ^a   Wostl, W ^a   Zell, M ^a   Zell, R ^a   more..

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Aspartic proteinase; Renin; Renin inhibitor

Indexed keywords

ANGIOTENSIN; CILAZAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDRALAZINE; HYDROCHLOROTHIAZIDE; RENIN; RENIN INHIBITOR; RESERPINE;

BLOOD PRESSURE; CHRONIC KIDNEY FAILURE; CONFERENCE PAPER; DRUG DEVELOPMENT; DRUG STRUCTURE; DRUG SYNTHESIS; KIDNEY INJURY; MARMOSET; MONKEY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PROTEINURIA;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; HUMANS; KIDNEY FAILURE; PIPERIDINES; RENIN;

EID: 0035273245     PISSN: 0014827X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-827X(01)01004-7     Document Type: Conference Paper

References (33)

1. Maintenance of blood pressure by the renin angiotensin system in normal man
2. The renin-angiotensin system: role in experimental and human hypertension
3. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial
4. Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases
5. Angiotensin-forming pathways in normal and failing human hearts
6. Functional and biochemical analysis of angiotensin II-forming pathways in the human heart
7. Natriuretic action of angiotensin(1-7)
8. Discovery of a distinct binding site for angiotensin II (3-8), a putative angiotensin IV receptor
9. Blood pressure effects of acute renin or angiotensin converting enzyme inhibition in essential hypertension
10. Immediate blood pressure effects of the renin inhibitor enalkiren and the ACE inhibitor enalaprilat
11. Clinical experience with the angiotensin II receptor antagonist losartan
12. Effects of blocking the angio II receptor, ACE and renin activity on the renal hemodynamics of normotensive guinea pigs
13. Renal circulation and blockade of the RAS. Is ACE inhibition the last word?
14. Renal and systemic effects of the renin inhibitor remikiren in patients with essential hypertension
15. Antihypertensive drug treatment: potential, expected and observed effects on stroke and coronary heart disease
16. Recent developments in renin inhibitors
17. Recent developments in renin inhibitors: part I
18. Recent developments in renin inhibitors: part II
19. Renin inhibition
20. Substituted piperidines-highly potent renin inhibitors due to induced fit adaptation of the active site
21. Piperidine renin inhibitors-compounds with improved physicochemical properties
22. Design of novel potent, non-peptide and orally active renin inhibitors
23. Structure-based drug design: the discovery of novel nonpeptide orally active inhibitors of human renin
24. Synthetic studies on anthracylinones. IX. Lithiation of N,N-dimethyl-naphthalenemethylamines and a new synthetic pathway to 2,3-naphthalides
25. Ro 42-5892 is a potent orally active renin inhibitor in primates
26. High human renin hypertension in transgenic rats
27. Blood pressure-independent effects in rats with human renin and angiotensinogen genes
28. NF-kappaB inhibition ameliorates angiotensinII-induced inflammatory damage in rats